索磷布韦、格卡瑞韦、哌仑他韦和利巴韦林作为难治性丙型肝炎患者的挽救疗法 - Suppr

Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients.

作者信息

Meszaros Magdalena, Truchi Régine, Ouzan Denis, Tran Albert, Bourlière Marc, Pageaux Georges-Philippe

机构信息

Hépato-Gastroentérologie, Hôpital Saint-Eloi, Montpellier, France.

Université Côte d'Azur, Nice, France.

出版信息

Hepatology. 2021 Oct;74(4):2304-2306. doi: 10.1002/hep.31909. Epub 2021 Jun 16.

DOI:10.1002/hep.31909

PMID:34008214

Abstract

摘要

相似文献

Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients.

Hepatology. 2021 Oct;74(4):2304-2306. doi: 10.1002/hep.31909. Epub 2021 Jun 16.

Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.

J Hepatol. 2020 Mar;72(3):441-449. doi: 10.1016/j.jhep.2019.10.020. Epub 2019 Nov 2.

Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.

J Hepatol. 2020 Mar;72(3):431-440. doi: 10.1016/j.jhep.2019.10.010. Epub 2019 Oct 23.

Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.

BMC Infect Dis. 2021 Apr 27;21(1):389. doi: 10.1186/s12879-021-06091-x.

Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.

Hepatology. 2018 Oct;68(4):1298-1307. doi: 10.1002/hep.30046. Epub 2018 Jul 25.

Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.

Hepatology. 2018 Feb;67(2):514-523. doi: 10.1002/hep.29541. Epub 2018 Jan 4.

Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV-infected Japanese Subjects in Phase 3 CERTAIN-1 and CERTAIN-2 Trials.

J Clin Pharmacol. 2020 Mar;60(3):331-339. doi: 10.1002/jcph.1524. Epub 2019 Sep 12.

Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study.

Adv Ther. 2019 Dec;36(12):3458-3470. doi: 10.1007/s12325-019-01123-0. Epub 2019 Oct 23.

[A case of HCV genotype 3b with compensated stage cirrhosis who have two times treatment-experienced with the use of glecaprevir/pibrentasvir combined with sofosbuvir and ribavirin for 16 weeks].

Zhonghua Gan Zang Bing Za Zhi. 2021 Dec 20;29(12):1194-1195. doi: 10.3760/cma.j.cn501113-20200526-00275.

Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China.

Medicine (Baltimore). 2021 Jun 18;100(24):e26312. doi: 10.1097/MD.0000000000026312.

引用本文的文献

Unlocking hope: HCV re-treatment strategy for patients with active hepatocellular carcinoma.

JHEP Rep. 2024 Apr 7;6(11):101093. doi: 10.1016/j.jhepr.2024.101093. eCollection 2024 Nov.

[Glecaprevir/pibrentasvir in combination with ribavirin as salvage therapy in chronic hepatitis C].

Rev Esp Quimioter. 2024 Jun;37(3):283-284. doi: 10.37201/req/020.2024. Epub 2024 Apr 19.

Effectiveness and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir as a Hepatitis C Virus Infection Salvage Therapy in the Real World: A Systematic Review and Meta-analysis.

Infect Dis Ther. 2022 Aug;11(4):1661-1682. doi: 10.1007/s40121-022-00666-0. Epub 2022 Jun 24.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献